Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 11:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TDF Clear all
Terminated Phase 4 Interventional Results available

Artery Elasticity After Switch From Epzicom to Truvada

NCT00998582
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 21, 2026, 11:09 PM EDT
Not listed Not applicable Interventional

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

NCT03275701
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Triumeq
Drug
Lead sponsor
Mills Clinical Research
Industry
Eligibility
50 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

NCT00074581
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
3,526 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-Exposure Prophylaxis in the Emergency Department

NCT04429971
View directory record Official record
Conditions
HIV/AIDS, PrEP
Interventions
PrEP screening program, PrEP starter pack
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 21, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, Placebo, NrtI
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Pasadena, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 21, 2026, 11:09 PM EDT
Not listed Not applicable Interventional

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

NCT00988780
View directory record Official record
Conditions
Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
Interventions
maraviroc, Placebo
Drug
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 21, 2026, 11:09 PM EDT
Terminated Phase 2 Interventional Results available

Emtricitabine/Tenofovir Alafenamide as Salvage ART

NCT02556333
View directory record Official record
Conditions
HIV
Interventions
FTC/TAF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 21, 2026, 11:09 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

ANCHORS Alcohol & Sexual Health Study: UH3 Project

NCT04331704
View directory record Official record
Conditions
Alcohol Use, Unspecified, Substance Use, Sex Behavior
Interventions
PrEP acronym (pre-exposure prophylaxis), Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 21, 2026, 11:09 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)

NCT03255915
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC), Placebo
Drug · Other
Lead sponsor
Oak Crest Institute of Science
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Not applicable Interventional Results available

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

NCT02251236
View directory record Official record
Conditions
HIV
Interventions
Stribild, Genvoya
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

NCT02603107
View directory record Official record
Conditions
HIV-1 Infection
Interventions
RTV, ATV, DRV, COBI, ATV/co, DRV/co, FTC/TDF, ABC/3TC, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
63
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study of TLC-ART 101 (ACTU 2001)

NCT05850728
View directory record Official record
Conditions
Human Immunodeficiency Virus, Treatment, Antiretroviral Therapy
Interventions
TLC-ART
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 11:09 PM EDT
Terminated Phase 4 Interventional Results available

Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

NCT00775606
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome
Interventions
Lopinavir 400 mg/ritonavir 100 mg, Efavirenz
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 21, 2026, 11:09 PM EDT
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

NCT07658976
View directory record Official record
Conditions
HIV Infection, Sexually Transmitted Infection
Interventions
HIV PrEP - choice of F/TDF, F/TAF, or CAB-LA, STI PEP - Doxycycline as Doxy-PEP, 3P mHealth package, Handout about HIV PrEP options available at the site, Standard-of-care HIV PrEP counseling from qualified study staff
Drug · Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years to 29 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Los Angeles, California • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B

NCT00410072
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Entecavir, Entecavir + Tenofovir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2013 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

NCT04535544
View directory record Official record
Conditions
Hepatitis D, Chronic
Interventions
JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Redwood City, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

NCT02121795
View directory record Official record
Conditions
HIV-1 Infection
Interventions
FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Results available

Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients

NCT01332227
View directory record Official record
Conditions
HIV, Combination Therapy
Interventions
Atazanavir, Ritonavir (heat-stable), Raltegravir, Tenofovir/Emtricitabine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2015 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Bioequivalence of Atripla in an Oral Liquid Formulation Compared With the Tablet Formulation in Healthy Volunteers

NCT00862823
View directory record Official record
Conditions
Healthy
Interventions
tenofovir, emtricitabine and efavirenz fixed dose tablet, tenofovir, emtricitabine and efavirenz tablet added to solution
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 21, 2026, 11:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

NCT02333045
View directory record Official record
Conditions
HIV
Interventions
Truvada qd, Maraviroc 300 qd
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 2 Interventional Results available

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

NCT00350272
View directory record Official record
Conditions
HIV Infections
Interventions
Elvucitabine, Lamivudine, Tenofovir, Efavirenz
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
25
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 21, 2026, 11:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)

NCT03510468
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tenofovir alafenamide, Rifapentine, Isoniazid (INH), Pyridoxine
Drug · Dietary Supplement
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 21, 2026, 11:09 PM EDT